Last updated on October 2017

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea


Brief description of study

Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea. Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.

Clinical Study Identifier: NCT02922231

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Petra Schongrundner

Daegu Catholic University Medical Center
Daegu, Korea, Republic of
  Connect »

Petra Schongrundner

DaeJeon Eulji University Hospital
Daejeon, Korea, Republic of
  Connect »

Petra Schongrundner

Kim Hugh Chul Internal Medicine
Seoul, Korea, Republic of
  Connect »

Petra Schongrundner

Korea Hemophilia Foundation
Seoul, Korea, Republic of
  Connect »